NasdaqGS:BNTXBiotechs
BioNTech (NasdaqGS:BNTX) Valuation Check After New Lung Cancer Data Highlights Oncology Pipeline Progress
Clinical data spotlight raises questions for BioNTech (NasdaqGS:BNTX) investors
BioNTech (NasdaqGS:BNTX) has put its oncology ambitions in focus after presenting fresh lung cancer data at the European Lung Cancer Congress in Copenhagen, covering late stage immunomodulators and antibody drug conjugates.
See our latest analysis for BioNTech.
Despite the positive lung cancer updates and a series of conference appearances in March, BioNTech’s recent momentum has been weak, with a 1 month share...